Latest Insider Transactions at Recursion Pharmaceuticals, Inc. (RXRX)
This section provides a real-time view of insider transactions for Recursion Pharmaceuticals, Inc. (RXRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of RECURSION PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of RECURSION PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 20
2021
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
55,383
+0.59%
|
-
|
|
Apr 20
2021
|
Robert Hershberg Director |
BUY
Conversion of derivative security
|
Direct |
6,250
+50.0%
|
-
|
|
Apr 20
2021
|
Robert Hershberg Director |
SELL
Conversion of derivative security
|
Direct |
6,250
-100.0%
|
-
|
|
Apr 20
2021
|
Tina Marriott Larson President and COO |
BUY
Other acquisition or disposition
|
Direct |
52,500
+50.0%
|
-
|
|
Apr 20
2021
|
Tina Marriott Larson President and COO |
SELL
Other acquisition or disposition
|
Direct |
52,500
-100.0%
|
-
|
|
Apr 20
2021
|
Dean Y Li Director |
BUY
Other acquisition or disposition
|
Direct |
596,390
+26.14%
|
-
|
|
Apr 20
2021
|
Dean Y Li Director |
SELL
Other acquisition or disposition
|
Direct |
596,390
-100.0%
|
-
|
|
Apr 20
2021
|
Dean Y Li Director |
BUY
Other acquisition or disposition
|
Indirect |
3,222,048
+50.0%
|
-
|
|
Apr 20
2021
|
Dean Y Li Director |
SELL
Other acquisition or disposition
|
Indirect |
3,222,048
-100.0%
|
-
|
|
Apr 20
2021
|
Dean Y Li Director |
BUY
Conversion of derivative security
|
Indirect |
55,383
+3.75%
|
-
|
|
Apr 20
2021
|
Michael Secora Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
528,762
+50.0%
|
-
|
|
Apr 20
2021
|
Michael Secora Chief Financial Officer |
SELL
Other acquisition or disposition
|
Direct |
528,762
-100.0%
|
-
|
|
Apr 20
2021
|
Michael Secora Chief Financial Officer |
BUY
Conversion of derivative security
|
Direct |
149,077
+21.99%
|
-
|
|
Apr 20
2021
|
Shafique Virani Chief Business Officer |
BUY
Other acquisition or disposition
|
Direct |
18,000
+50.0%
|
-
|
|
Apr 20
2021
|
Shafique Virani Chief Business Officer |
SELL
Other acquisition or disposition
|
Direct |
18,000
-100.0%
|
-
|
|
Apr 20
2021
|
Investment CO Pjsc Mubadala > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
13,026,009
+32.59%
|
-
|
|
Apr 20
2021
|
Lux Ventures Iv, L.P. |
BUY
Conversion of derivative security
|
Indirect |
17,187,095
+49.86%
|
-
|
|
Apr 20
2021
|
Lux Ventures Iv, L.P. |
SELL
Conversion of derivative security
|
Indirect |
17,187,095
-100.0%
|
-
|
|
Apr 20
2021
|
Lux Ventures Iv, L.P. |
BUY
Conversion of derivative security
|
Indirect |
17,174,594
+49.98%
|
-
|
|
Apr 16
2021
|
Investment CO Pjsc Mubadala > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,777,777
+50.0%
|
$49,999,986
$18.0 P/Share
|
|
Apr 16
2021
|
Lux Ventures Iv, L.P. |
BUY
Open market or private purchase
|
Indirect |
100,000
+50.0%
|
$1,800,000
$18.0 P/Share
|
|
Apr 16
2021
|
Blake Borgeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+0.09%
|
-
|
|
Apr 16
2021
|
Terry Ann Burrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+4.71%
|
-
|
|
Apr 16
2021
|
R. Martin Chavez Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+50.0%
|
-
|
|
Apr 16
2021
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+50.0%
|
-
|
|
Apr 16
2021
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,889
+2.28%
|
-
|